BRCA2

There are 165 papers on BRCA2 in aging research: 3 trials and 90 observational studies in people, 7 in animals, 3 in cells, 52 reviews. The newest story, Nov 13, 2026: “Model improves disease prediction by tracking genetic risk with age”.

Gene

165 papers study it31 findings

HGNCNCBI GeneTaxon

16 new papers in 30 daysSee all 165 papers on BRCA2

At a glance

A human cohort links BRCA2 protein-truncating variant burden with lifespan. Independent labs associate pathogenic variants with higher breast, pancreatic and prostate cancer risk. Much of this work names National Cancer Institute and National Institutes of Health funding; papers report company affiliations and declared ties.

31 findings in 19 papers from 2006 to 2026, 6 of them since May 2026

Independent labs found the same change in people. 16 independent labs in 16 countries.

“Highly penetrant BRCA1 c.4065_4068del (p.Asn1355fs) and BRCA2 c.2808_2811del (p.Ala938Profs) variants showed age-specific cumulative risks of 37.6% and 31% by age 60, respectively,”
A National Genomic Framework for Breast Cancer Risk Stratification in UAEResearch Square2026doi:10.21203/rs.3.rs-11056849/v1

2 of its findings point the other way.

Humans: replicated by independent labs. Cells and mice: a single group. Worms or flies: nothing yet.
  • 16 independent labs in 16 countries
  • 2 findings against
  • Funders: National Cancer Institute and others
  • 10 of 29 findings with company ties
  • Human trial3
  • Humans90
  • Animals6
  • Model organisms1
  • Cells3
  • In silico6

Effects

6

Endogenous cell survival

is required forin human cells1

1 study
  1. BRCA2 is required for endogenous cell survival in human cells (hypomorphic missense variants in the DNA-binding domain).

    “70 candidate hypomorphic missense variants in the DNA-binding domain of BRCA2 reduce homologous recombination DNA repair activity and endogenous cell survival”

    Cellshypomorphic missense variants in the DNA-binding domain

    Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants

    Nature communications

Homologous recombination DNA repair activity

is required forin human cells1

1 study
  1. BRCA2 is required for homologous recombination DNA repair activity in human cells (hypomorphic missense variants in the DNA-binding domain).

    “70 candidate hypomorphic missense variants in the DNA-binding domain of BRCA2 reduce homologous recombination DNA repair activity and endogenous cell survival”

    Cellshypomorphic missense variants in the DNA-binding domain

    Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants

    Nature communications

AMH

no changein humans1

1 study
  1. BRCA2 was not clearly linked with AMH in humans (7% lower; 95% CI, 31% lower to 26% higher).

    “not gBRCA2 compared with controls (7% lower; 95% CI, 31% lower to 26% higher; P = .64).”

    Humansfemales

    Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

More on AMH

Age at natural menopause

no changein humans1HR 1.06

1 study
  1. BRCA2 was not clearly linked with age at natural menopause in humans (adjusted HR 1.06 (95% CI, 0.87-1.30)).

    “Overall, no association was found between BRCA1/2 mutation status and ANM (adjusted hazard ratio [HR] = 1.06 [95% CI, 0.87-1.30]).”

    Humansfemales

    Do BRCA1/2 mutation carriers have an earlier onset of natural menopause?

    Menopause (New York, N.Y.)

homologous chromosome synapsis

is required forin rats1

1 study
  1. BRCA2 is required for homologous chromosome synapsis in rats (shown by knockout).

    “Aspermatogenesis in the Brca2-/- rats is due to a failure of homologous chromosome synapsis.”

    Animalsshown by knockouttestismales

    Characterizing a rat Brca2 knockout model

    Oncogene

Fertility

is required forin rats1

1 study
  1. BRCA2 is required for fertility in rats (shown by knockout, both sexes).

    “Brca2-/- rats show a phenotype of growth inhibition and sterility in both sexes.”

    Animalsshown by knockout, both sexes

    Characterizing a rat Brca2 knockout model

    Oncogene

Upstream

1

Aged hens

downin chickens1

1 study
  1. Aged hens decrease BRCA2 in chickens (validated by qRT-PCR).

    “BRCA2 and FBN1 were significantly downregulated in Fanconi anemia (FA) and TGF-β signaling pathways in W100”

    Animalsvalidated by qRT-PCRmagnumfemales

    Histological and molecular difference in albumen quality between post-adolescent hens and aged hens

    Poultry science

More on Aged hens

Associations

16

Breast cancer

upin humans3

3 studies
  1. BRCA2 is associated with breast cancer in humans (Emirati population; BRCA2 c.2808_2811del (p.Ala938Profs)) (31% cumulative risk by age 60).

    “Highly penetrant BRCA1 c.4065_4068del (p.Asn1355fs) and BRCA2 c.2808_2811del (p.Ala938Profs) variants showed age-specific cumulative risks of 37.6% and 31% by age 60, respectively,”

    HumansEmirati population; BRCA2 c.2808_2811del (p.Ala938Profs)

    Inherited gene variants linked to breast cancer risk in UAE

    Research SquarePreprint

  2. BRCA2 is linked with a higher risk of breast cancer in humans (pathogenic variant carriers) (66.1% (95% CI, 57.5%-72.9%)).

    “66.1% (95% CI, 57.5%-72.9%) for BRCA2 pathogenic variant carriers, compared with 12.0% (95% CI, 11.2%-12.8%) in the general population”

    Humanspathogenic variant carriersbreastfemales

    Breast and Ovarian Cancer Among Individuals Undergoing BRCA1 and BRCA2 Testing

    JAMA network open

  3. BRCA2 raises the risk of breast cancer in humans.

    “BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genes, documented to inherit significantly increase a chance of developing BRCA”

    Review

    BREAST CANCER AND DIAGNOSTIC METHODS: UNDERSTANDING THE ROLE OF BRCA1 AND BRCA2

    Georgian medical news

More on Breast cancer

Prostate cancer

upin humans3

3 studies
  1. BRCA2 is linked with a higher risk of prostate cancer in humans (BRCA2 pathogenic variant carriers) (SIR = 3.6, 95% CI 1.9-6.8).

    “For BRCA2 PV carriers, increased risks of pancreatic (SIR = 6.6, 95% CI 3.8-11.6), prostate (SIR = 3.6, 95% CI 1.9-6.8) and stomach (SIR = 3.1, 95% CI 1.01-9.8) cancer were observed”

    HumansBRCA2 pathogenic variant carriers

    Risks of non-breast, non-ovarian cancers for BRCA1 and BRCA2 pathogenic variant carriers: a prospective cohort study

    BMC medicine

  2. BRCA2 raises the risk of prostate cancer in humans.

    “Germline BRCA2 mutation carriers represent the most clearly defined high-risk group, with evidence of earlier onset, higher incidence, and a greater proportion of aggressive disease”

    Review

    High-risk prostate cancer screening – More Bang for our buck?

    Journal of Clinical Urology

  3. BRCA2 raises the risk of prostate cancer in humans (early and aggressive disease).

    “BRCA2 mutations have been added as risk factors for early and aggressive disease.”

    Reviewearly and aggressive diseasemales

    EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    European urology

More on Prostate cancer

Pancreatic cancer

upin humans3RR 1.56

3 studies
  1. BRCA2 is linked with a higher risk of pancreatic cancer in humans (BRCA2 pathogenic variant carriers) (SIR = 6.6, 95% CI 3.8-11.6).

    “For BRCA2 PV carriers, increased risks of pancreatic (SIR = 6.6, 95% CI 3.8-11.6), prostate (SIR = 3.6, 95% CI 1.9-6.8) and stomach (SIR = 3.1, 95% CI 1.01-9.8) cancer were observed”

    HumansBRCA2 pathogenic variant carriers

    Risks of non-breast, non-ovarian cancers for BRCA1 and BRCA2 pathogenic variant carriers: a prospective cohort study

    BMC medicine

  2. BRCA2 is linked with a higher risk of pancreatic cancer in humans (pathogenic germline variants) (RR 1.56, 95% CI, 0.50 to 3.63).

    “Additionally, BRCA2 families showed an increased risk of pancreatic cancer (RR 1.56; 95% CI, 0.50 to 3.63).”

    Humanspathogenic germline variants

    Associations between Pathogenic Germline Variants in BRCA and Non-Breast/Non-Ovarian Cancer Types in the German Population

    Geburtshilfe und Frauenheilkunde

  3. BRCA2 raises the risk of pancreatic cancer in humans (germline BRCA2 mutation) (up to 22-fold risk).

    “hereditary breast and ovarian cancer with BRCA2 mutation (up to 22-fold risk)”

    Reviewgermline BRCA2 mutation

    Genetic Predisposition to Pancreatic Cancer: A Systematic Review of Hereditary Syndromes and Familial Aggregation

    Cancers

More on Pancreatic cancer

Ovarian cancer

upin humans2

2 studies
  1. BRCA2 is linked with a higher risk of ovarian cancer in humans (24.1% (95% CI, 15.1-36.6)).

    “The lifetime risk of ovarian cancer was 55.0% (95% CI, 48.8-61.9) for a BRCA1 carrier and 24.1% (95% CI, 15.1-36.6) for a BRCA2 carrier.”

    Humansfemales

    Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers

    JAMA surgery

  2. BRCA2 is linked with a higher risk of ovarian cancer in humans (pathogenic variant carriers) (29.3% (95% CI, 14.2%-41.7%)).

    “and 29.3% (95% CI, 14.2%-41.7%) for BRCA2 pathogenic variant carriers, compared with 1.5% (95% CI, 1.3%-1.7%) in the general population.”

    Humanspathogenic variant carriersovaryfemales

    Breast and Ovarian Cancer Among Individuals Undergoing BRCA1 and BRCA2 Testing

    JAMA network open

More on Ovarian cancer

Gastric cancer

upin humans2RR 1.88

2 studies
  1. BRCA2 is linked with a higher risk of gastric cancer in humans (BRCA2 pathogenic variant carriers) (SIR = 3.1, 95% CI 1.01-9.8).

    “For BRCA2 PV carriers, increased risks of pancreatic (SIR = 6.6, 95% CI 3.8-11.6), prostate (SIR = 3.6, 95% CI 1.9-6.8) and stomach (SIR = 3.1, 95% CI 1.01-9.8) cancer were observed”

    HumansBRCA2 pathogenic variant carriers

    Risks of non-breast, non-ovarian cancers for BRCA1 and BRCA2 pathogenic variant carriers: a prospective cohort study

    BMC medicine

  2. BRCA2 is linked with a higher risk of gastric cancer in humans (pathogenic germline variants) (RR 1.88, 95% CI: 0.75-3.87).

    “The relative risk of gastric cancer was higher in BRCA2 carriers compared to BRCA1 carriers (gBRCA1 RR 1.42; 95% CI: 0.65-2.69 vs. gBRCA2 RR 1.88; 95% CI: 0.75-3.87).”

    Humanspathogenic germline variants

    Associations between Pathogenic Germline Variants in BRCA and Non-Breast/Non-Ovarian Cancer Types in the German Population

    Geburtshilfe und Frauenheilkunde

More on Gastric cancer

Homologous recombination deficiency

downin humans1

1 study
  1. BRCA2 is associated with homologous recombination deficiency in humans (32% with hypomorphic variants versus 83% with pathogenic variants and 7% with benign variants).

    “32% of tumors with hypomorphic variants and corresponding loss of heterozygosity for BRCA2 display homologous recombination deficiency (HRD) compared to 83% of tumors with PVs”

    Humanshypomorphic variants with corresponding BRCA2 loss of heterozygosity, compared with pathogenic variantstumor

    Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants

    Nature communications

Age at breast cancer diagnosis

upin humans1

1 study
  1. BRCA2 is associated with age at breast cancer diagnosis in humans (34 strong hypomorphic variants compared with pathogenic variants).

    “are associated with moderate risks of female breast cancer and later ages of diagnosis than pathogenic variants (PVs)”

    Humans34 strong hypomorphic variants compared with pathogenic variantsfemales

    Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants

    Nature communications

Female breast cancer

upin humans1

1 study
  1. BRCA2 is associated with female breast cancer in humans (34 strong hypomorphic missense variants) (moderate risks).

    “The 34 “strong” hypomorphs with greatest effects on function are associated with moderate risks of female breast cancer”

    Humans34 strong hypomorphic missense variantsfemales

    Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants

    Nature communications

More on Female breast cancer

Hepatocellular carcinoma

upin humans1

1 study
  1. BRCA2 is linked with a higher risk of hepatocellular carcinoma in humans (combined analysis across all populations; rare variants at 0.1% MAF).

    “A significant BRCA2 association was also observed in the combined analysis at a MAF of 0.1%”

    Humanscombined analysis across all populations; rare variants at 0.1% MAF

    Multi-ancestry sequencing analysis in 293,141 participants identifies predisposition DNA repair genes associated with HCC risk

    JHEP reports : innovation in hepatology

More on Hepatocellular carcinoma

Myeloproliferative neoplasm

upin humans1

1 study
  1. BRCA2 is associated with myeloproliferative neoplasm in humans (ET 3/10 BRCA2 mutations, the highest proportion among subtypes).

    “The common FA signaling pathway gene mutations in MPN patients are BRCA2, FANCD2”

    Humans

    Mutation characteristics and prognosis of patients with Fanconi anemia signaling pathway gene mutation myeloproliferative neoplasm

    Zhonghua yi xue za zhi

More on Myeloproliferative neoplasm

All 16

Funding

4 grants since 2019

Gouvernement du Canada | Canadian Institutes of Health ResearchCA$639KNational Cancer Institute$742KBreast Cancer Research Foundation225K

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    BRCA2 protein-truncating variants are linked with shorter lifespan in a human cohort; homozygous Brca2 knockout shortens rat lifespan, independently replicated. Independent labs link pathogenic variants with human breast cancer risk. NIH and National Cancer Institute are each named on eight findings; two papers declare company ties, and two findings have company-affiliated authors.

  2. Summary rewritten as its findings changed.

    As it read before

    A preprint human study links the BRCA2 c.2808_2811del (p.Ala938Profs) variant to breast cancer in Emirati women. Another human study links BRCA2 carrier status to higher ovarian cancer risk in women; a review describes increased cancer risk in women.

  3. Summary written from the findings.

Latest

Dec 2025: 3Jan 2026: 8Feb 2026: 10Mar 2026: 15Apr 2026: 5May 2026: 6Jun 2026: 3Jul 2026: 7Aug 2026: 8Sep 2026: 10Oct 2026: 10Nov 2026: 893 papers in 12 months
medRxiv

Model improves disease prediction by tracking genetic risk with age

Across 28 diseases, median scores for distinguishing future cases from others were 0.95 versus 0.92 for a model keeping common genetic effects constant with age.Across 28 diseases, median scores for distinguishing future cases from others were 0.95 versus 0.92 for a model keeping common genetic effects constant with age.

Preprint: computational studyAI & data

See all 165 papers on BRCA2